182 related articles for article (PubMed ID: 23073054)
1. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
Leonard JP
Clin Adv Hematol Oncol; 2012 Aug; 10(8):540-2. PubMed ID: 23073054
[No Abstract] [Full Text] [Related]
2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
3. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
[TBL] [Abstract][Full Text] [Related]
5. A treatment for activated B-cell-like DLBCL?
Zinzani PL
Lancet Oncol; 2014 Aug; 15(9):916-7. PubMed ID: 25042201
[No Abstract] [Full Text] [Related]
6. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in indolent lymphomas.
Sousou T; Friedberg J
Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
[TBL] [Abstract][Full Text] [Related]
8. Antibody therapy for non-Hodgkin's lymphoma.
Ansell SM
Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
[TBL] [Abstract][Full Text] [Related]
9. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
10. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
11. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
[TBL] [Abstract][Full Text] [Related]
12. [Advances in the research of anti-CD20 therapeutic monoclonal antibodies].
Deng CL; Zou J; Song HF
Yao Xue Xue Bao; 2013 Oct; 48(10):1515-20. PubMed ID: 24417077
[TBL] [Abstract][Full Text] [Related]
13. [Recent progress in rituximab therapy and its resistance--how do we overcome?].
Hatake K; Yokoyama M; Terui Y
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1177-82. PubMed ID: 17687198
[TBL] [Abstract][Full Text] [Related]
14. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
15. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
[TBL] [Abstract][Full Text] [Related]
16. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
Bhat SA; Czuczman MS
Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
[TBL] [Abstract][Full Text] [Related]
17. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
Jourdan E; Richard B
Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of anti-CD20 antibodies.
Gopal AK; Press OW
J Lab Clin Med; 1999 Nov; 134(5):445-50. PubMed ID: 10560936
[No Abstract] [Full Text] [Related]
19. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
